ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. Drug Shortages. Biosimilar Exclusivity. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.3561: PATIENT Act of 2023. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act. DEA Quotas.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Medicare/Medicaid MMM
Medicare Part D Reform. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. H.R.1352: Increasing Access to Biosimilars Act of 2023. Medicare Rebate Penalty. Inflation Reduction Act (Pub.L.117-169).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRAIG BURTON | — |
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Copyright/Patent/Trademark CPT
Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140: Patent Eligibility Restoration Act of 2023. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.8134: Restoring Americas Leadership in Innovation Act of 2024.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Budget/Appropriations BUD
FDA Funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Trade (domestic/foreign) TRD
General Trade Issues. Drug Supply Chain. H.R.7085: BIOSECURE Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARIN HESSLER | — |
| ILHAAM JAFFER | — |
| PETER KELBEL | — |
| KATHERINE RAAB | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.